Autologous Hematopoietic Cell Transplant (HCT) Sends Multiple Sclerosis into Remission

by Dr. Trupti Shirole on December 30, 2014 at 11:36 PM
 Autologous Hematopoietic Cell Transplant (HCT) Sends Multiple Sclerosis into Remission

A new study published in the JAMA has revealed that for patients with relapsing-remitting multiple sclerosis (RRMS), high-dose immunosuppressive therapy (HDIT) with autologous hematopoietic cell transplant (HCT) is related with sustained remission and improvements in neurologic function.

Most patients with RRMS who received disease-modifying therapies experience breakthrough disease. Autologous (i.e. using a patient's own cells) HCT has been studied in RRMS with the goal of removing disease-causing immune cells and resetting the immune system.


Researchers examined the effectiveness of early intervention with HDIT/HCT for patients with RRMS and breakthrough disease. They found that of the 24 patients who received HDIT/HCT, the overall rate of event-free survival was 78.4 percent at 3-years, which was defined as survival without death or disease from a loss of neurologic function, clinical relapse or new lesions observed on imaging, while progression-free survival and clinical relapse-free survival were 90.9 percent and 86.3 percent, respectively, at 3-years. The adverse events were consistent with the expected toxic effect of HDIT/HCT and no acute treatment-related neurologic adverse events were seen. Researchers also noted improvements in neurologic disability, quality-of-life and functional scores.

The study is titled 'The Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS)'.

Source: Medindia
Font : A-A+



Recommended Readings

Latest Genetics & Stem Cells News

New Gene Therapy to Treat Genetic Brain Disorder
NGN-401 is a first ever new gene therapy discovered to cure a rare genetic brain disorder called Rett Syndrome.
Early-Stage Stem Cell Trial for Progressive Multiple Sclerosis
Among MS patients, the stem cells showed a neuroprotective role, guarding nerve cells from further decline.
Human Genetics Unravels Mysteries of Digestive Disorders
New possibilities for research on digestive diseases have been set by complete decoding of the Y chromosome.
World's First CRISPR-Based Gene Therapy for Blood Disorders
UK has given the green light to the world's inaugural gene therapy for sickle-cell disease and thalassemia.
Genotype Linked to Short-Lifespan Affects 1 in 25 People
1 in 25 people had a genotype linked to short lifetime, which includes BRCA2 and LDLR genes, that reduced lifespan by seven years, and six years respectively.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Autologous Hematopoietic Cell Transplant (HCT) Sends Multiple Sclerosis into Remission Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests